Mehrnaz Gharaee-Kermani1, Biao Hu, Sem H Phan, Margaret R Gyetko. 1. University of Michigan Medical School, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, 2215 Fuller Road, 11R, Ann Arbor, MI 48105, USA. nazy@umich.edu
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and frequently fatal form of interstitial lung disease for which there are no proven drug therapies. The pathogenesis of IPF is complex and the urokinase-type plasminogen activator (uPA)/plasminogen system participates in the repair process. The balance between the activating enzyme uPA, and its inhibitor PAI-1, is a critical determinant of the amount of scar development that follows. OBJECTIVE: To address the role of urokinase in the pathogenesis of pulmonary fibrosis and its implications for therapy. METHODS: We reviewed a spectrum of therapeutic strategies and focused on fibrinolytic and anticoagulant drugs for IPF patients. RESULTS/ CONCLUSION: There is currently a search for new pharmacotherapeutic agents that may modulate the fibrogenic pathways in IPF. Either blocking PAI-1 or using uPA itself may be a promising new therapeutic strategy.
BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and frequently fatal form of interstitial lung disease for which there are no proven drug therapies. The pathogenesis of IPF is complex and the urokinase-type plasminogen activator (uPA)/plasminogen system participates in the repair process. The balance between the activating enzyme uPA, and its inhibitor PAI-1, is a critical determinant of the amount of scar development that follows. OBJECTIVE: To address the role of urokinase in the pathogenesis of pulmonary fibrosis and its implications for therapy. METHODS: We reviewed a spectrum of therapeutic strategies and focused on fibrinolytic and anticoagulant drugs for IPF patients. RESULTS/ CONCLUSION: There is currently a search for new pharmacotherapeutic agents that may modulate the fibrogenic pathways in IPF. Either blocking PAI-1 or using uPA itself may be a promising new therapeutic strategy.
Authors: Jianyong Zhong; Hai-Chun Yang; Valentina Kon; Agnes B Fogo; Daniel A Lawrence; Ji Ma Journal: Lab Invest Date: 2014-03-31 Impact factor: 5.662
Authors: Amarnath S Marudamuthu; Shwetha K Shetty; Yashodhar P Bhandary; Sophia Karandashova; Michael Thompson; Venkatachalem Sathish; Galina Florova; Taryn B Hogan; Christina M Pabelick; Y S Prakash; Yoshikazu Tsukasaki; Jian Fu; Mitsuo Ikebe; Steven Idell; Sreerama Shetty Journal: J Biol Chem Date: 2015-02-03 Impact factor: 5.157
Authors: Carlos Daniel Vasconcelos; António Carlos Ferreira; Patrícia Caetano Mota; Miguel Luz Soares; Bruno A Lima; Elisabetta Manduchi; Jason H Moore; Natália Melo; Hélder Novais-Bastos; José Miguel Pereira; Susana Guimarães; Conceição Souto Moura; José Agostinho Marques; António Morais Journal: J Mol Med (Berl) Date: 2022-08-19 Impact factor: 5.606
Authors: Gerie J Glas; Johannes Muller; Jan M Binnekade; Berry Cleffken; Kirsten Colpaert; Barry Dixon; Nicole P Juffermans; Paul Knape; Marcel M Levi; Bert G Loef; David P Mackie; Manu Malbrain; Marcus J Schultz; Koenraad F van der Sluijs Journal: Trials Date: 2014-03-25 Impact factor: 2.279